Skip to main navigation Skip to search Skip to main content

Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group

  • Smita Bhatia
  • , Wendy Landier
  • , Muyun Shangguan
  • , Lindsey Hageman
  • , Alexandra N. Schaible
  • , Andrea R. Carter
  • , Cara L. Hanby
  • , Wendy Leisenring
  • , Yutaka Yasui
  • , Nancy M. Kornegay
  • , Leo Mascarenhas
  • , A. Kim Ritchey
  • , Jacqueline N. Casillas
  • , David S. Dickens
  • , Jane Meza
  • , William L. Carroll
  • , Mary V. Relling
  • , F. Lennie Wong
  • City of Hope National Med Center
  • University of California at Los Angeles
  • Fred Hutchinson Cancer Research Center
  • University of Alberta
  • St. Jude Children Research Hospital
  • University of Southern California
  • University of Pittsburgh
  • Spectrum Health
  • University of Nebraska Medical Center
  • New York University

Research output: Contribution to journalArticlepeer-review

313 Scopus citations

Abstract

Purpose: Systemic exposure to mercaptopurine (MP) is critical for durable remissions in children with acute lymphoblastic leukemia (ALL). Nonadherence to oral MP could increase relapse risk and also contribute to inferior outcome in Hispanics. This study identified determinants of adherence and described impact of adherence on relapse, both overall and by ethnicity. Patients and Methods: A total of 327 children with ALL (169 Hispanic; 158 non-Hispanic white) participated. Medication event-monitoring system caps recorded date and time of MP bottle openings. Adherence rate, calculated monthly, was defined as ratio of days of MP bottle opening to days when MP was prescribed. Results: After 53,394 person-days of monitoring, adherence declined from 94.7% (month 1) to 90.2% (month 6; P < .001). Mean adherence over 6 months was significantly lower among Hispanics (88.4% v 94.8%; P < .001), patients age ≥ 12 years (85.8% v 93.1%; P < .001), and patients from single-mother households (80.6% v 93.1%; P = .001). A progressive increase in relapse was observed with decreasing adherence (reference: adherence ≥ 95%; 94.9% to 90%: hazard ratio [HR], 4.1; 95% CI,1.2 to 13.5; P = .02; 89.9% to 85%: HR, 4.0; 95% CI, 1.0 to 15.5; P = .04; < 85%: HR. 5.7; 95% CI, 1.9 to 16.8; P = .002). Cumulative incidence of relapse (± standard deviation) was higher among Hispanics (16.5% ± 4.0% v 6.3% ± 2.2%; P = .02). Association between Hispanic ethnicity and relapse (HR, 2.6; 95% CI, 1.1 to 6.1; P = .02) became nonsignificant (HR, 1.8; 95% CI, 0.6 to 5.2; P = .26) after adjusting for adherence and socioeconomic status. At adherence rates ≥ 90%, Hispanics continued to demonstrate higher relapse, whereas at rates < 90%, relapse risk was comparable to that of non-Hispanic whites. Conclusion: Lower adherence to oral MP increases relapse risk. Ethnic difference in relapse risk differs by level of adherence-an observation currently under investigation.

Original languageEnglish
Pages (from-to)2094-2101
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number17
DOIs
StatePublished - 10 Jun 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this